Neurobiological effects of melatonin as related to cancer

European Journal of Cancer Prevention

Volumn 16, Issue 6, 2007, Pages 511-516

  Hoang, Ba X ^a,b   Shaw, David G ^a   Pham, Phuong T ^a   Levine, Stephen A ^a  

^a School of Pharmacy   (United States)

^b Allergy Research Group   (United States)

Author keywords

Cancer pathogenesis; Cancer prevention; Excitotoxins; Melatonin; Membrane calming; Membrane excitability; Nutrition; Sedatives

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CISPLATIN; ETOPOSIDE; FLUOROURACIL; MELATONIN; MELATONIN RECEPTOR; NITRIC OXIDE; PROTEIN P53;

AGING; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ASTROCYTOMA; BONE PAIN; BRAIN CANCER; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CELL CYCLE REGULATION; CELL KILLING; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; CIRCADIAN RHYTHM; CLUSTER HEADACHE; CORE TEMPERATURE; DEGENERATIVE DISEASE; DEPRESSION; HORMONE ACTION; HUMAN; IMMUNOMODULATION; KIDNEY CANCER; LUNG CANCER; MIGRAINE; NEOPLASM; NERVE CELL EXCITABILITY; NEUROBIOLOGY; NONHUMAN; PARKINSON DISEASE; PHYSIOLOGY; PINEAL BODY; PRIORITY JOURNAL; RADIATION SICKNESS; SEIZURE; SKIN CANCER; SLEEP; SLEEP DISORDER; SLEEP WAKING CYCLE; THERMOREGULATION; WORK SCHEDULE;

AGING; ANTINEOPLASTIC AGENTS; BIOLOGICAL CLOCKS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; EXCITATORY AMINO ACID AGENTS; HEADACHE; HUMANS; MELATONIN; MEMBRANE POTENTIALS; MODELS, BIOLOGICAL; NEOPLASMS; NEURODEGENERATIVE DISEASES; NEUROTOXINS; NEUROTRANSMITTER AGENTS; PAIN; SEIZURES; SLEEP;

EID: 37349053724     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e32801023dc     Document Type: Article

References (85)

1. Acuna-Castroviejo D, Escames G, Macias M, Munoz Hoyos A, Molina Carballo A, Arauzo M, et al. (1995). Cell protective role of melatonin in the brain. J Pineal Res 19:57-63.
2. Anisimov V (2001). Melatonin and colon carcinogenesis. In: Bartsch C, Bartsch H, Blask DE, Cardinali DP, Hrushesky WJM, Mecke D, editors. The pineal gland and cancer. Berlin: Springer-Verlag; pp. 240-258.
3. Ayar A, Kutlu S, Yilmaz B, Kelestimur H (2001). Melatonin inhibits spontaneous and oxytocin-induced contractions of rat myometrium in vitro. Neuro Endocrinol Lett 22:199-207.
4. Aydogan S, Yerer MB, Goktas A (2006). Melatonin and nitric oxide. J Endocrinol Invest 29:281-287.
5. Bazil CW, Short D, Crispin D, ZhengW(2000). Patients with intractable epilepsy have low melatonin, which increases following seizures. Neurology 55:1746-1748.
6. Blask DE (1993). Melatonin in oncology. In: Yu HS, Reiter RJ, editors. Melatonin biosynthesis, physiological effects and clinical applications. Boca Raton: CRC Press; pp. 347-351.
7. Blask DE (1997). Systemic, cellular, and molecular aspects of melatonin action on experimental breast carcinogenesis. In: Stevens RG, Wilson BW, Anderson LE, editors. The melatonin hypothesis- breast cancer and the use of electric powder. Columbus: Battle Press; pp. 189-203.
8. Blask DE (2001). An overview of the neuroendocrine regulation of experimental tumor growth by melatonin and its analogues and the therapeutic use of melatonin in oncology. In: Bartsch C, Bartsch H, Blask DE, Cardinali DP, Hrushesky WJM, Mecke D, editors. The pineal gland and cancer. Berlin: Springer-Verlag; pp. 309-342.
9. Blask DE, Sauer LA, Dauchy RT, Holowachuk EW, Ruhoff MS, Kopff HS (1999). Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events. Cancer Res 59:4693-4701.
10. Blask DE, Sauer LA, Dauchy RT (2002). Melatonin as a chronobiotic/ anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem 2:113-132.
11. Blask DE, Dauchy RT, Sauer LA (2005). Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal. Endocrine 27:179-188.
12. Bubenik GA (2002). Gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci 47:2336-2348.
13. Burkhardt S, Tan DX, Manchester LC, Hardeland R, Reiter RJ (2001). Detection and quantification of the antioxidant melatonin in Montmorency and Balaton tart cherries (Prunus cerasus). J Agric Food Chem 49:4898-4902.
14. Cagnacci A, Krauchi K, Wirz-Justice A, Volpe A (1997). Homeostatic versus circadian effects of melatonin on core body temperature in humans. J Biol Rhythms 12:509-517.
15. Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ (2005). A review of the multiple actions of melatonin on the immune system. Endocrine 27:189-200.
16. Cavalheiro EA, Olney JW (2001). Glutamate antagonists: deadly liaisons with cancer. Proc Natl Acad Sci U S A 98:5947-5948.
17. Cini G, Coronnello M, Mini E, Neri B (1998). Melatonin's growth-inhibitory effect on hepatoma AH 130 in the rat. Cancer Lett 125:51-59.
18. Coloma FM, Niles LP (1988). Melatonin enhancement of [3H]-gamma- aminobutyric acid and [3H]muscimol binding in rat brain. Biochem Pharmacol 37:1271-1274.
19. Cos S, Fernandez R (2000). Melatonin effects on intercellular junctional communication in MCF-7 human breast cancer cells. J Pineal Res 29:166-171.
20. Cos S, Sanchez-Barcelo EJ (2000a). Melatonin and mammary pathological growth. Front Neuroendocrinol 21:133-170.
21. Cos S, Sanchez-Barcelo EJ (2000b). Melatonin, experimental basis for a possible application in breast cancer prevention and treatment. Histol Histopathol 15:637-647.
22. Dauchy RT, Blask DE, Sauer LA, Brainard GC, Krause JA (1999). Dim light during darkness stimulates tumor progression by enhancing tumor fatty acid uptake and metabolism. Cancer Lett 144:131-136.
23. Dawson D, Encel N (1993). Melatonin and sleep in humans. J Pineal Res 15:1-12.
24. Dawson D, Gibbon S, Singh P (1996). The hypothermic effect of melatonin on core body temperature: is more better? J Pineal Res 20:192-197.
25. Delagrange P, Jockers R (2003). Melatonin and energy homeostasis: peripheral versus central regulation. Minerva Endocrinol 28:313-320.
26. Escames G, Macias M, Leon J, Garcia J, Khaldy H, Martin M, et al. (2001). Calcium-dependent effects of melatonin inhibition of glutamatergic response in rat striatum. J Neuroendocrinol 13:459-466.
27. Fauteck J, Schmidt H, Lerchl A, Kurlemann G, Wittkowski W (1999). Melatonin in epilepsy: first results of replacement therapy and first clinical results. Biol Signals Recept 8:105-110.
28. Greaves M (2000). Cancer: the evolutionary legacy. Oxford, United Kingdom: Oxford University Press.
29. Guerrero JM, Reiter RJ (2002). Melatonin-immune system relationships. Curr Top Med Chem 2:167-179.
30. Hardeland R (2005). Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine 27:119-130.
31. Hill SM, Collins A, Kiefer TL (2000). The modulation of oestrogen receptor-alpha activity by melatonin in MCF-7 human breast cancer cells. Eur J Cancer 36 (Suppl 4):117-118.
32. Hoang BX, Levin SA, Pham P, Shaw DG (2006). Hypothesis of the cause and development of neoplasms. Eur J Cancer Prev (in press).
33. Hruskesky WJM (2001). Melatonin cancer therapy. In: Bartsch C, Bartsch H, Blask DE, Cardinali DP, Hrushesky WJM, Mecke D, editors. The pineal gland and cancer. Berlin: Springer-Verlag; pp. 476-508.
34. Karasek M, Reiter RJ, Cardinali DP, Pawlikowski M (2002). Future of melatonin as a therapeutic agent. Neuro Endocrinol Lett 23 (Suppl 1):118-121.
35. Kostrzewa RM, Segura-Aguilar J (2003). Novel mechanisms and approaches in the study of neurodegeneration and neuroprotection. A review. Neurotox Res 5:375-383.
36. Li GL, Li P, Yang XL (2001). Melatonin modulates gamma-aminobutyric acid(A) receptor-mediated currents on isolated carp retinal neurons. Neurosci Lett 301:49-53.
37. Lima AC, Louzada PR, De Mello FG, Ferreira ST (2003). Neuroprotection against Abeta and glutamate toxicity by melatonin: are GABA receptors involved? Neurotox Res 5:323-327.
38. Lissoni P (1998). Melatonin and cancer treatment. In: Watson RR, editor. Melatonin in the promotion of health. Boca Raton: CRC Press.
39. Lissoni P, Resentini M, Mauri R, Esposti D, Esposti G, Rossi D, et al. (1986). Effects of tetrahydrocannabinol on melatonin secretion in man. Horm Metab Res 18:77-78.
40. Lissoni P, Barni S, Ardizzoia A, Tancini G, Conti A, Maestroni G (1994a). A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. Cancer 73:699-701.
41. Lissoni P, Barni S, Tancini G, Ardizzoia A, Ricci G, Aldeghi R, et al. (1994b). A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer 69:196-199.
42. Lissoni P, Brivio F, Brivio O, Fumagalli L, Gramazio F, Rossi M, et al. (1995a). Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients. J Biol Regul Homeost Agents 9:31-33.
43. Lissoni P, Barni S, Meregalli S, Fossati V, Cazzaniga M, Esposti D, et al. (1995b). Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer 71:854-856.
44. Lissoni P, Pittalis S, Rovelli F, Vigore L, Roselli MG, Brivio F (1995c). Interleukin-2, melatonin and interleukin-12 as a possible neuroimmune combination in the biotherapy of cancer. J Biol Regul Homeost Agents 9:63-66.
45. Lissoni P, Brivio O, Brivio F, Barni S, Tancini G, Crippa D, et al. (1996a). Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma. J Pineal Res 21:239-242.
46. Lissoni P, Meregalli S, Nosetto L, Barni S, Tancini G, Fossati V, et al. (1996b). Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology 53:43-46.
47. Lissoni P, Barni S, Mandala M, Ardizzoia A, Paolorossi F, Vaghi M, et al. (1999a). Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 35:1688-1692.
48. Lissoni P, Tancini G, Paolorossi F, Mandala M, Ardizzoia A, Malugani F, et al. (1999b). Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study. J Pineal Res 26:169-173.
49. Lissoni P, Rovelli F, Malugani F, Bucovec R, Conti A, Maestroni GJ (2001). Anti-angiogenic activity of melatonin in advanced cancer patients. Neuro Endocrinol Lett 22:45-47.
50. Maestroni GJ, Conti A (1996). Melatonin in human breast cancer tissue: association with nuclear grade and estrogen receptor status. Lab Invest 75:557-561.
51. Manchester LC, Tan DX, Reiter RJ, Park W, Monis K, Qi W (2000). High levels of melatonin in the seeds of edible plants: possible function in germ tissue protection. Life Sci 67:3023-3029.
52. Mayo JC, Sainz RM, Tan DX, Hardeland R, Leon J, Rodriguez C, et al. (2005). Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. J Neuroimmunol 165:139-149.
53. McLellan TM, Gannon GA, Zamecnik J, Gil V, Brown GM (1999). Low doses of melatonin and diurnal effects on thermoregulation and tolerance to uncompensable heat stress. J Appl Physiol 87:308-316.
54. Mills E, Wu P, Seely D, Guyatt G (2005). Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J Pineal Res 39:360-366.
55. Molina-Carballo A, Munoz-Hoyos A, Reiter RJ, Sanchez-Forte M, Moreno-Madrid F, Rufo-Campos M, et al. (1997). Utility of high doses of melatonin as adjunctive anticonvulsant therapy in a child with severe myoclonic epilepsy: two years' experience. J Pineal Res 23:97-105.
56. Moretti RM, Marelli MM, Maggi R, Dondi D, Motta M, Limonta P (2000). Antiproliferative action of melatonin on human prostate cancer LNCaP cells. Oncol Rep 7:347-351.
57. Morrey KM, McLachlan JA, Serkin CD, Bakouche O (1994). Activation of human monocytes by the pineal hormone melatonin. J Immunol 153:2671-2680.
58. Murch SJ, Simmons CB, Saxena PK (1997). Melatonin in feverfew and other medicinal plants. Lancet 350:1598-1599.
59. Pandi-Perumal SR, Srinivasan V, Maestroni GJ, Cardinali DP, Poeggeler B, Hardeland R (2006). Melatonin. FEBS J 273:2813-2838.
60. Papavasiliou PS, Cotzias GC, Duby SE, Steck AJ, Bell M, Lawrence WH (1972). Melatonin and parkinsonism. JAMA 221:88-89.
61. Peres MF (2005). Melatonin, the pineal gland and their implications for headache disorders. Cephalalgia 25:403-411.
62. Poeggeler B, Thuermann S, Dose A, Schoenke M, Burkhardt S, Hardeland R (2002). Melatonin's unique radical scavenging properties: roles of its functional substituents as revealed by a comparison with its structural analogs. J Pineal Res 33:20-30.
63. Pozo D, Reiter RJ, Calvo JR, Guerrero JM (1994). Physiological concentrations of melatonin inhibit nitric oxide synthase in rat cerebellum. Life Sci 55:PL455-PL460.
64. Raghavendra V, Agrewala JN, Kulkarni SK (2000). Melatonin reversal of lipopolysacharides-induced thermal and behavioral hyperalgesia in mice. Eur J Pharmacol 395:15-21.
65. Rato AG, Pedrero JG, Martinez MA, del Rio B, Lazo PS, Ramos S (1999). Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J 13:857-868.
66. Reppert SM, Weaver DR (1995). Melatonin madness. Cell 83:1059-1062.
67. Riabykh TP, Nikolaeva TG, Bodrova NB (2000). Effects of biorhythm regulator melatonin on DNA synthesis in short-term cultures of human malignant tumors. Vestn Ross Akad Med Nauk 8:30-33.
68. Roth JA, Kim BG, Lin WL, Cho MI (1999). Melatonin promotes osteoblast differentiation and bone formation. J Biol Chem 274:22041-22047.
69. Rufo-Campos M (2002). Melatonin and epilepsy. Rev Neurol 35 (Suppl 1):S51-S58.
70. Sandyk R (1990). Pineal melatonin functions and the depression of Parkinson's disease: a hypothesis. Int J Neurosci 51:73-77.
71. Sauer LA, Dauchy RT, Blask DE (2001). Polyunsaturated fatty acids, melatonin, and cancer prevention. Biochem Pharmacol 61:1455-1462.
72. Schuller HM, Orloff M (1998). Tobacco-specific carcinogenic nitrosamines. Ligands for nicotinic acetylcholine receptors in human lung cancer cells. Biochem Pharmacol 55:1377-1384.
73. Shiu SY, Li L, Xu JN, Pang CS, Wong JT, Pang SF (1999). Melatonin-induced inhibition of proliferation and G1/S cell cycle transition delay of human choriocarcinoma JAr cells: possible involvement of MT2 (MEL1B) receptor. J Pineal Res 27:183-192.
74. Simonneaux V, Ribelayga C (2003). Generation of the melatonin endocrine message in mammals: a review of the complex regulation of melatonin synthesis by norepinephrine, peptides, and other pineal transmitters. Pharmacol Rev 55:325-395.
75. Soybir G, Topuzlu C, Odabas O, Dolay K, Bilir A, Koksoy F (2003). The effects of melatonin on angiogenesis and wound healing. Surg Today 33:896-901.
76. Srinivasan V, Pandi-Perumal SR, Maestroni GJ, Esquifino AI, Hardeland R, Cardinali DP (2005). Role of melatonin in neurodegenerative diseases. Neurotox Res 7:293-318.
77. Tan DX, Manchester LC, Hardeland R, Lopez-Burillo S, Mayo JC, Sainz RM, et al. (2003). Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res 34:75-78.
78. Turjanski AG, Saenz DA, Doctorovich F, Estrin DA, Rosenstein RE (2001). Nitrosation of melatonin by nitric oxide: a computational study. J Pineal Res 31:97-101.
79. Ubeda A, Trillo MA, House DE, Blackman CF (1995). Melatonin enhances junctional transfer in normal C3H/10T1/2 cells. Cancer Lett 91:241-245.
80. Vega-Naredo I, Poeggeler B, Sierra-Sanchez V, Caballero B, Tomas-Zapico C, Alvarez-Garcia O, et al. (2005). Melatonin neutralizes neurotoxicity induced by quinolinic acid in brain tissue culture. J Pineal Res 39:266-275.
81. Wang XC, Zhang J, Yu X, Han L, Zhou ZT, Zhang Y, et al. (2005). Prevention of isoproterenol-induced tau hyperphosphorylation by melatonin in the rat. Sheng Li Xue Bao 57:7-12.
82. Winczyk K, Pawlikowski M, Karasek M (2001). Melatonin and RZR/ROR receptor ligand CGP 52608 induce apoptosis in the murine colonic cancer. J Pineal Res 31:179-182.
83. Wu FS, Yang YC, Tsai JJ (1999). Melatonin potentiates the GABA(A) receptor-mediated current in cultured chick spinal cord neurons. Neurosci Lett 260:177-180.
84. Yon JH, Carter LB, Reiter RJ, Jevtovic-Todorovic V (2006). Melatonin reduces the severity of anesthesia-induced apoptotic neurodegeneration in the developing rat brain. Neurobiol Dis 21:522-530.
85. Zeise ML, Semm P (1985). Melatonin lowers excitability of guinea pig hippocampal neurons in vitro. J Comp Physiol [A] 157:23-29.